Medimmune Limited

Viela Bio, Inc.

Boston Pharmaceuticals, Inc.

University of Helsinki

Ronald Herbst

Stacey Drabic

Melissa Marie Damschroder

Anthony Coyle

Herren Wu

Manuel Baca

Changshou Gao

Partha S Chowdhury

William Dall'Acqua

Peter Kiener

Scott A Hammond

Claire Louise Dobson

Xiaodong Xiao

Darren Schofield

Godfrey Rainey

Reena Varkey

Qun Du

Ping Tsui

Yariv Mazor

Michelle Morrow

Srinath Kasturirangan

Thomas Thisted

Michael Oberst

Vaheh Oganesyan

Brian Lobo

Prakash Manikwar

Catherine Ettinger

Simon Dovedi

Jonathan Seaman

Gianluca Carlesso

Shabazz Novarra

Brian Michael Naiman

Laura Carter

Jodi Karnell

David Kenneth Spencer

Luba Grinberg

Kristen Pollizzi

Kari Alitalo

Ching Ching Leow

Peter Emtage

Simo Syrjala

Karl Lemstrom

Jane Connor

Manual Baca

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit

Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).

CD40L-Fc fusion polypeptides and methods of use thereof

The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.

Methods of protecting a solid organ transplant tissue with angiopoietin-2 antibodies

CD40L-specific TN3-derived scaffolds and methods of use thereof

The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Humanized anti-CD19 antibodies

Growing community of inventors

Gaithersburg, MD, United States of America

Ronald Herbst